Answers are grounded in this paper and cite their sources.
Cross-sectional analysis identifies distinct genetic profiles in metastatic prostate cancer, suggesting therapeutic targets.
Purpose: This study used the Seoul National University Hospital FIRST-Cancer Panel (v3.2.2) to identify potentially druggable targets in prostate cancer. We compared genetic alterations between primary, treatmentnaive, hormone-sensitive prostate cancer (HSPC) tissue obtained at initial diagnosis and metastatic, castrationresistant prostate cancer (CRPC) tissue obtained after disease recurrence to identify candidate genes associated with the metastatic, castration-resistant phenotype. Because this was a cross-sectional comparison, the findings represent associations only and do not establish a causal role in metastasis.Materials and Methods: We analyzed samples from 93 patients with prostate cancer using the FIRST-Cancer Panel, which included 192 genes, 25 fusion genes, 8 microsatellite instability markers, and 45 druggable genomic targets. The cohort comprised 80 primary, treatment-naive HSPC tumor samples obtained at diagnosis and 13 distant metastatic CRPC samples obtained after recurrence. DNA was extracted from formalin-fixed paraffin-embedded tissue, sequenced using the NextSeq 550Dx platform, and analyzed with the Seoul National University Hospital CPM Solid v3.7 pipeline. Oncoprint analysis using cBioPortal and survival analyses were performed to assess clinical implications, and GraphPad Prism was used for correlation analysis.Results: Patient age, microsatellite instability status, and tumor mutational burden were comparable between the groups, but oncoprint analysis showed distinct alteration patterns. Primary tumors most frequently showed alterations in FOXA1, RB1, BRCA2, TP53, and SPOP, whereas metastatic samples most frequently showed alterations in FANCA, TMPRSS2, ERG, PTEN, and TP53, consistent with previous reports implicating these genes in advanced prostate cancer. In this exploratory comparison, UGT1A1, NOTCH3, and MAP3K4 were altered more frequently in metastatic samples than in primary samples. In external, aggregated cBioPortal cohorts, UGT1A1 and NOTCH3 alterations were associated with poorer 5-year overall survival rates (<60%).Conclusion: Targeted sequencing showed distinct genetic profiles between primary and metastatic prostate cancers. FANCA, TMPRSS2, ERG, PTEN, and TP53 alterations were more common in metastatic samples, consistent with established roles in advanced disease. UGT1A1 and NOTCH3 emerged as candidate genes that were more frequently altered in metastatic disease and were associated with worse survival in external cohorts. Given the cross-sectional design and small number of metastatic samples, these findings should be interpreted as associations rather than causal evidence. Further studies are warranted to evaluate these genes as potential therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: